Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 38Terminated 6Unknown 3Active not recruiting 3Recruiting 2

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Non-Small-Cell Lung 56Squamous Cell Carcinoma of Head and Neck 31Lung Neoplasms 17Head and Neck Neoplasms 17Urinary Bladder Neoplasms 16Oropharyngeal Neoplasms 14Parkinson Disease 4, Autosomal Dominant Lewy Body 11Nasopharyngeal Carcinoma 11Carcinoma 10Small Cell Lung Carcinoma 9Carcinoma, Squamous Cell 9Uterine Cervical Neoplasms 8Pancreatic Neoplasms 8Ovarian Neoplasms 8Carcinoma, Transitional Cell 8Neoplasm Metastasis 7Mouth Neoplasms 7Breast Neoplasms 7Triple Negative Breast Neoplasms 6Recurrence 6Neoplasms 6Melanoma 6Gallbladder Neoplasms 6Esophageal Squamous Cell Carcinoma 6Esophageal Neoplasms 6Colorectal Neoplasms 6Biliary Tract Neoplasms 6Mesothelioma, Malignant 5Medulloblastoma 5Laryngeal Neoplasms 5

Interventions

Oxaliplatin 7Fluorouracil 7Leucovorin 6pembrolizumab 4Paclitaxel 4Capecitabine 4Radiotherapy 3Radiation 3Nivolumab 3Cisplatin 3zimberelimab 2tislelizumab 2durvalumab 2Trastuzumab 2Taxes 2Levoleucovorin 2Irinotecan 2zanidatamab 1tucatinib 1trifluridine tipiracil drug combination 1tremelimumab 1trastuzumab deruxtecan 1spartalizumab 1quemliclustat 1obinutuzumab 1naptumomab estafenatox 1lenvatinib 1futibatinib 1dehydroftorafur 1cixutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Adenocarcinoma Of Esophagus × Cisplatin × Clear all
NCT05152147 2026-05-19

HERIZON-GEA-01

Jazz Pharmaceuticals

Phase 3 Active not recruiting
920 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

NCT04210115 2026-05-13

KEYNOTE 975

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
703 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT05945823 2026-04-09

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Taiho Oncology, Inc.

Phase 2 Active not recruiting
53 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡